Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

27.26 -0.36 (-1.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
News headline image
Why These 2 Biotech Stocks Made Big Moves Late Thursday ↗
Markets kept powering higher on the day. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Where ACADIA Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
11 Analysts Have This to Say About ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
Analyst Ratings for ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Strategic Fit of ACP-101 Promises Future Revenue Growth for Acadia Pharmaceuticals: Analyst ↗
Tuesday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for hyperphagia (a false... 
Via Benzinga
News headline image
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACADIA Pharmaceuticals's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
What 22 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
ACADIA Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
3 Penny Stocks That Could Skyrocket in the Next 12 Months ↗
Find the top penny stocks to buy, and you can make a fortune. Pick the wrong one and there are also plenty of horrors. 
Via InvestorPlace
News headline image
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Over $5M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Analyst Ratings for ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Records 52-Week High Tuesday Morning
Via Investor Brand Network
News headline image
Top 5 Health Care Stocks That Should Keep You Up At Night ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher ↗
ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. What Else? 
Via Benzinga
News headline image
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.